Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition
Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system and has a poor response to radiotherapy and chemotherapy. To date, it is urgent to find effective biomarkers for the prevention and treatment of ccRCC. The occurrence and development of ccRCC is...
Gespeichert in:
| Veröffentlicht in: | Journal of Cancer 2020, Vol.11 (5), p.1151-1161 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1161 |
|---|---|
| container_issue | 5 |
| container_start_page | 1151 |
| container_title | Journal of Cancer |
| container_volume | 11 |
| creator | Yuan, ChangFei Xiong, ZhiYong Shi, Jian Peng, JingTao Meng, XianGui Wang, Cheng Hu, WenJun Ru, ZeYuan Xie, KaiRu Yang, HongMei Chen, Ke Zhang, XiaoPing |
| description | Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system and has a poor response to radiotherapy and chemotherapy. To date, it is urgent to find effective biomarkers for the prevention and treatment of ccRCC. The occurrence and development of ccRCC is closely related to metabolic disturbances. Palmitoyl protein thioesterase 2 (PPT2) is a lysosomal thioesterase which is highly associated with metabolism, and it has never been studied in ccRCC. In this study, we first revealed PPT2 is significantly downregulated in ccRCC, and its expression level is highly correlated with clinicopathological parameters of ccRCC patients. Our ROC curve analyses evaluated the potential of PPT2 as a novel diagnostic marker and prognostic factor. Functional experiment results showed overexpression of PPT2 represses the proliferation, migration and invasion of ccRCC cells
. Mechanistic investigations demonstrated that overexpression of PPT2 represses the ccRCC progression by reducing epithelial-to-mesenchymal transition (EMT). In conclusion, PPT2 is downregulated in ccRCC. Decreased PPT2 expression may be considered as a novel diagnostic marker and prognostic factor and serve as a therapeutic target for ccRCC. |
| doi_str_mv | 10.7150/jca.36477 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6959065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2342359643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-439d871b9211f5824445a85784aaadf56503a4831b69ace9eacfa28152ff54ed3</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpaEKaQ_9AMfTSHpxan7YugWDyBYEsYXsWs_J4V4ttbSQ7dI_551GySUiii4Z5n3kZ5iXkBy2OSyqLv2sLx1yJsvxCDmjFy1wrJb6-q_fJUYzrIj2uWSn4N7LPqZaKK3pAHm7uMeD_TcAYnR8y32az2Zxlt_jcwpiNK8zqDiFkNXZdEgbodmUNwbrB95DNgl--Oiy2iWmmpCyzs41L452DLh993mPEwa62fTKYBxiiG9PAd7LXQhfx6OU_JP_Oz-b1ZX59c3FVn17nVhR8zAXXTVXShWaUtrJiQggJlSwrAQBNK5UsOIiK04XSYFEj2BZYRSVrWymw4YfkZOe7mRY9NhaHMUBnNsH1ELbGgzMflcGtzNLfG6WlLpRMBr9fDIK_mzCOpnfRpkPAgH6KhnHBuNRK8IT--oSu_RTS4RIldcUVY1Ik6s-OssHHGLB9W4YW5ilbk7I1z9km9uf77d_I1yT5I-eHoOY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598362254</pqid></control><display><type>article</type><title>Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Yuan, ChangFei ; Xiong, ZhiYong ; Shi, Jian ; Peng, JingTao ; Meng, XianGui ; Wang, Cheng ; Hu, WenJun ; Ru, ZeYuan ; Xie, KaiRu ; Yang, HongMei ; Chen, Ke ; Zhang, XiaoPing</creator><creatorcontrib>Yuan, ChangFei ; Xiong, ZhiYong ; Shi, Jian ; Peng, JingTao ; Meng, XianGui ; Wang, Cheng ; Hu, WenJun ; Ru, ZeYuan ; Xie, KaiRu ; Yang, HongMei ; Chen, Ke ; Zhang, XiaoPing</creatorcontrib><description>Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system and has a poor response to radiotherapy and chemotherapy. To date, it is urgent to find effective biomarkers for the prevention and treatment of ccRCC. The occurrence and development of ccRCC is closely related to metabolic disturbances. Palmitoyl protein thioesterase 2 (PPT2) is a lysosomal thioesterase which is highly associated with metabolism, and it has never been studied in ccRCC. In this study, we first revealed PPT2 is significantly downregulated in ccRCC, and its expression level is highly correlated with clinicopathological parameters of ccRCC patients. Our ROC curve analyses evaluated the potential of PPT2 as a novel diagnostic marker and prognostic factor. Functional experiment results showed overexpression of PPT2 represses the proliferation, migration and invasion of ccRCC cells
. Mechanistic investigations demonstrated that overexpression of PPT2 represses the ccRCC progression by reducing epithelial-to-mesenchymal transition (EMT). In conclusion, PPT2 is downregulated in ccRCC. Decreased PPT2 expression may be considered as a novel diagnostic marker and prognostic factor and serve as a therapeutic target for ccRCC.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.36477</identifier><identifier>PMID: 31956361</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Antibodies ; Cancer therapies ; Cell culture ; Cell growth ; Fatty acids ; Fluorides ; Kidney cancer ; Medical prognosis ; Medical research ; Membranes ; Metastasis ; Proteins ; Research Paper ; Tumorigenesis</subject><ispartof>Journal of Cancer, 2020, Vol.11 (5), p.1151-1161</ispartof><rights>The author(s).</rights><rights>2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-439d871b9211f5824445a85784aaadf56503a4831b69ace9eacfa28152ff54ed3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959065/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959065/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31956361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, ChangFei</creatorcontrib><creatorcontrib>Xiong, ZhiYong</creatorcontrib><creatorcontrib>Shi, Jian</creatorcontrib><creatorcontrib>Peng, JingTao</creatorcontrib><creatorcontrib>Meng, XianGui</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Hu, WenJun</creatorcontrib><creatorcontrib>Ru, ZeYuan</creatorcontrib><creatorcontrib>Xie, KaiRu</creatorcontrib><creatorcontrib>Yang, HongMei</creatorcontrib><creatorcontrib>Chen, Ke</creatorcontrib><creatorcontrib>Zhang, XiaoPing</creatorcontrib><title>Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system and has a poor response to radiotherapy and chemotherapy. To date, it is urgent to find effective biomarkers for the prevention and treatment of ccRCC. The occurrence and development of ccRCC is closely related to metabolic disturbances. Palmitoyl protein thioesterase 2 (PPT2) is a lysosomal thioesterase which is highly associated with metabolism, and it has never been studied in ccRCC. In this study, we first revealed PPT2 is significantly downregulated in ccRCC, and its expression level is highly correlated with clinicopathological parameters of ccRCC patients. Our ROC curve analyses evaluated the potential of PPT2 as a novel diagnostic marker and prognostic factor. Functional experiment results showed overexpression of PPT2 represses the proliferation, migration and invasion of ccRCC cells
. Mechanistic investigations demonstrated that overexpression of PPT2 represses the ccRCC progression by reducing epithelial-to-mesenchymal transition (EMT). In conclusion, PPT2 is downregulated in ccRCC. Decreased PPT2 expression may be considered as a novel diagnostic marker and prognostic factor and serve as a therapeutic target for ccRCC.</description><subject>Antibodies</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Cell growth</subject><subject>Fatty acids</subject><subject>Fluorides</subject><subject>Kidney cancer</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Membranes</subject><subject>Metastasis</subject><subject>Proteins</subject><subject>Research Paper</subject><subject>Tumorigenesis</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU1r3DAQhkVpaEKaQ_9AMfTSHpxan7YugWDyBYEsYXsWs_J4V4ttbSQ7dI_551GySUiii4Z5n3kZ5iXkBy2OSyqLv2sLx1yJsvxCDmjFy1wrJb6-q_fJUYzrIj2uWSn4N7LPqZaKK3pAHm7uMeD_TcAYnR8y32az2Zxlt_jcwpiNK8zqDiFkNXZdEgbodmUNwbrB95DNgl--Oiy2iWmmpCyzs41L452DLh993mPEwa62fTKYBxiiG9PAd7LXQhfx6OU_JP_Oz-b1ZX59c3FVn17nVhR8zAXXTVXShWaUtrJiQggJlSwrAQBNK5UsOIiK04XSYFEj2BZYRSVrWymw4YfkZOe7mRY9NhaHMUBnNsH1ELbGgzMflcGtzNLfG6WlLpRMBr9fDIK_mzCOpnfRpkPAgH6KhnHBuNRK8IT--oSu_RTS4RIldcUVY1Ik6s-OssHHGLB9W4YW5ilbk7I1z9km9uf77d_I1yT5I-eHoOY</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Yuan, ChangFei</creator><creator>Xiong, ZhiYong</creator><creator>Shi, Jian</creator><creator>Peng, JingTao</creator><creator>Meng, XianGui</creator><creator>Wang, Cheng</creator><creator>Hu, WenJun</creator><creator>Ru, ZeYuan</creator><creator>Xie, KaiRu</creator><creator>Yang, HongMei</creator><creator>Chen, Ke</creator><creator>Zhang, XiaoPing</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2020</creationdate><title>Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition</title><author>Yuan, ChangFei ; Xiong, ZhiYong ; Shi, Jian ; Peng, JingTao ; Meng, XianGui ; Wang, Cheng ; Hu, WenJun ; Ru, ZeYuan ; Xie, KaiRu ; Yang, HongMei ; Chen, Ke ; Zhang, XiaoPing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-439d871b9211f5824445a85784aaadf56503a4831b69ace9eacfa28152ff54ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Cell growth</topic><topic>Fatty acids</topic><topic>Fluorides</topic><topic>Kidney cancer</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Membranes</topic><topic>Metastasis</topic><topic>Proteins</topic><topic>Research Paper</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, ChangFei</creatorcontrib><creatorcontrib>Xiong, ZhiYong</creatorcontrib><creatorcontrib>Shi, Jian</creatorcontrib><creatorcontrib>Peng, JingTao</creatorcontrib><creatorcontrib>Meng, XianGui</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Hu, WenJun</creatorcontrib><creatorcontrib>Ru, ZeYuan</creatorcontrib><creatorcontrib>Xie, KaiRu</creatorcontrib><creatorcontrib>Yang, HongMei</creatorcontrib><creatorcontrib>Chen, Ke</creatorcontrib><creatorcontrib>Zhang, XiaoPing</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, ChangFei</au><au>Xiong, ZhiYong</au><au>Shi, Jian</au><au>Peng, JingTao</au><au>Meng, XianGui</au><au>Wang, Cheng</au><au>Hu, WenJun</au><au>Ru, ZeYuan</au><au>Xie, KaiRu</au><au>Yang, HongMei</au><au>Chen, Ke</au><au>Zhang, XiaoPing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2020</date><risdate>2020</risdate><volume>11</volume><issue>5</issue><spage>1151</spage><epage>1161</epage><pages>1151-1161</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system and has a poor response to radiotherapy and chemotherapy. To date, it is urgent to find effective biomarkers for the prevention and treatment of ccRCC. The occurrence and development of ccRCC is closely related to metabolic disturbances. Palmitoyl protein thioesterase 2 (PPT2) is a lysosomal thioesterase which is highly associated with metabolism, and it has never been studied in ccRCC. In this study, we first revealed PPT2 is significantly downregulated in ccRCC, and its expression level is highly correlated with clinicopathological parameters of ccRCC patients. Our ROC curve analyses evaluated the potential of PPT2 as a novel diagnostic marker and prognostic factor. Functional experiment results showed overexpression of PPT2 represses the proliferation, migration and invasion of ccRCC cells
. Mechanistic investigations demonstrated that overexpression of PPT2 represses the ccRCC progression by reducing epithelial-to-mesenchymal transition (EMT). In conclusion, PPT2 is downregulated in ccRCC. Decreased PPT2 expression may be considered as a novel diagnostic marker and prognostic factor and serve as a therapeutic target for ccRCC.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>31956361</pmid><doi>10.7150/jca.36477</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1837-9664 |
| ispartof | Journal of Cancer, 2020, Vol.11 (5), p.1151-1161 |
| issn | 1837-9664 1837-9664 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6959065 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies Cancer therapies Cell culture Cell growth Fatty acids Fluorides Kidney cancer Medical prognosis Medical research Membranes Metastasis Proteins Research Paper Tumorigenesis |
| title | Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A51%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20PPT2%20Represses%20the%20Clear%20Cell%20Renal%20Cell%20Carcinoma%20Progression%20by%20Reducing%20Epithelial-to-mesenchymal%20Transition&rft.jtitle=Journal%20of%20Cancer&rft.au=Yuan,%20ChangFei&rft.date=2020&rft.volume=11&rft.issue=5&rft.spage=1151&rft.epage=1161&rft.pages=1151-1161&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.36477&rft_dat=%3Cproquest_pubme%3E2342359643%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598362254&rft_id=info:pmid/31956361&rfr_iscdi=true |